title: Intraventricular nerve growth factor infusion: a possible treatment for neurological deficits following hypoxic-ischemic brain injury in infants.
abstract: OBJECTIVE
  Hypoxic-ischemic brain injuries in childhood are associated with poor neurological outcome. Unfortunately, no new therapeutic approaches have been proposed. Recently, animal studies show that nerve growth factor (NGF) can reduce neurological deficits following hypoxic-ischemic brain injuries. The objective of this study is to demonstrate the therapeutic effects of intraventricular NGF infusion in severe post-ischemic damage.
  
  
  METHODS
  Two infants, aged 9 and 8 months, with hypoxic-ischemic brain damage, secondary to prolonged cardiorespiratory arrest and stabilized after the conventional treatment, were treated with intraventricular NGF infusion. Before the therapy both infants were comatose with asymmetrical tetraparesis; their Glasgow Coma Scale (GCS) was 4 and 5, respectively. One month after the treatment, their GCS was 8 and 9, respectively. EEG examinations performed after the NGF infusion showed an increased alpha/theta ratio. MRI showed a reduction of malacic areas in the brain. A SPECT study, performed only in one infant, demonstrated that the NGF treatment resulted in an improvement of regional cerebral perfusion in right temporal and occipital cortices.
  
  
  METHODS
  The drug utilized was 2.5S NGF purified and lyophilized from male mouse submaxillary glands. NGF infusion was started about 30 days after the hypoxic-ischemic brain injury. 0.1 mg NGF was administered via the external drainage catheter into the right cerebral ventricle once a day for 10 days consecutively.
  
  
  CONCLUSIONS
  Our observations are interesting, but further studies are necessary to confirm the effects of NGF in hypoxic-ischemic brain injuries in infants.
authors.affiliation: Pediatric Intensive Care Unit, Catholic University Medical School, Rome, Italy. achiaretti@yahoo.it
authors.forename: Antonio
authors.initials: A
authors.lastname: Chiaretti
authors.forename: Orazio
authors.initials: O
authors.lastname: Genovese
authors.forename: Riccardo
authors.initials: R
authors.lastname: Riccardi
authors.forename: Concezio
authors.initials: C
authors.lastname: Di Rocco
authors.forename: Daniela
authors.initials: D
authors.lastname: Di Giuda
authors.forename: Paolo
authors.initials: P
authors.lastname: Mariotti
authors.forename: Silvia
authors.initials: S
authors.lastname: Pulitanò
authors.forename: Marco
authors.initials: M
authors.lastname: Piastra
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Polidori
authors.forename: Giovanna Stefania
authors.initials: GS
authors.lastname: Colafati
authors.forename: Luigi
authors.initials: L
authors.lastname: Aloe
mesh_terms: D002552:Cerebral Ventricles; D004569:Electroencephalography; D006801:Humans; D020925:Hypoxia-Ischemia, Brain / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D007223:Infant; D007263:Infusions, Parenteral; D008279:Magnetic Resonance Imaging; D020932:Nerve Growth Factor / Q000008:administration & dosage* / Q000627:therapeutic use*; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome
chemical_list: D020932:Nerve Growth Factor